Further knowledge of how GA affects brain-resident immune cells and infiltrating immune cells, and how GA modulates STAT-associated immune-responses and neurodegeneration may facilitate the development of more effective therapeutic approaches for progressive MS. This evidence concerns the gene SOAT1 and myeloid sarcoma.